BioSpecifics Technologies Corp

BioSpecifics Technologies — Investor Presentation (February 2016)

26 slides from BioSpecifics Technologies's investor presentation, Feb 26, 2016

  1. Slide 1: Innovators in the development & commercialization of injectable collagenase

    Innovators in the development & commercialization of INJECTABLE COLLAGENASE ema — Cp BioSpecifics February 2016

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation includes “forward-looking statements” within the meaning of, and made pursuant to the safe harbor provisions of, the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact, including statements regarding

  3. Slide 3: Company Overview (NASDAQ: BSTC)

    Company Overview (NASDAQ: BSTC) 60060 6 Originator of collagenase based-therapies Profitable biopharma company with lean corporate structure and stock buy-back program Receives revenues from XIAFLEX® milestones, royalties on net sales, mark-up on COGS and sublicense income by partner Endo $8.25M lum

  4. Slide 4: Unlocking Vast Potential of XIAFLEX

    Unlocking Vast Potential of XIAFLEX® XIAFLEX: First-in-class, minimally invasive nonsurgical treatment for conditions caused by collagen accumulation with limited current treatment options BioSpecifics has positive clinical results in 12 indications Drive R&D in new indications to early proof-of-con

  5. Slide 5: Marketed XIAFLEX Indications

    Marketed XIAFLEX Indications: First, Effective Nonsurgical Treatment Options YTD Demand Growth of 44% Through 11/30/15

  6. Slide 6: Dupuytren's Contracture

    XIAFLEX® for Dupuytren’s Contracture Definition & Key Complications Collagen cord in hand causing one or more fingers to contract toward the palm Limits range of motion and impairs quality of life Affects up to 7% of adults in the U.S. Pre-treatment: Post-treatment: Source: Endo International ple

  7. Slide 7: Commercial Highlights for Dupuytren's Contracture

    Commercial Highlights for Dupuytren’s Contracture ~6,400 demand vials in 3Q15 in U.S. 14% year-over-year increase in demand vials ~1.2 vials/patient First commercial sale in Japan in September 2015 Updated U.S. label including recurrence and retreatment data approved in May 2015 E.U. label expansion

  8. Slide 8: Peyronie's Disease

    XIAFLEX® for Peyronie’s Disease Definition & Key Complications Inelastic collagen causing penile curvature; penis can bend at 90° angle during erection in severe cases Associated with increased pain, painful erections, palpable plaque, penile deformity and erectile dysfunction Potential loss of self

  9. Slide 9: Commercial Highlights for Peyronie's Disease

    Commercial Highlights for Peyronie’s Disease ~7,500 demand vials in 3Q15 in U.S. 33% year-over-year growth in demand vials ~4.5 vials/patient Continued commercial progress and growth with certified physicians and new patients As of 3Q15 there were 2,325 certified physicians and 11,600 cumulative pat

  10. Slide 10: Pipeline Indications

    XIAFLEX® Pipeline Indications

  11. Slide 11: Pipeline Programs

    XIAFLEX® Pipeline Programs Future Revenue-Generating Opportunities i 1 Phase 2b recently Cellulite ehiced . Phase 2b to initiate Ae hese endo > following 1016 FDA P: discussion Human Phase 2 top-line Lipoma results in 2016 ; Endo has license fanin€ TS for further ji development peaked > Initiate tri

  12. Slide 12: Adhesive Capsulitis

    XIAFLEX® for Adhesive Capsulitis Potential to be Only FDA Approved Nonsurgical Therapy © Inflammation and thickening of shoulder capsule due to collagen Limits range of motion of shoulder Common available treatment options are often painful and can require anesthesia Long-term intensive physical the

  13. Slide 13: Phase 2b Study Results of XIAFLEX in Adhesive Capsulitis

    Phase 2b Study Results of XIAFLEX® in Adhesive Capsulitis/Frozen Shoulder Syndrome Phase 2a Results 321 patient double-blind, placebo-controlled study ra evaluating safety and efficacy in Stage 2 (frozen stage) E50 unilateral idiopathic frozen shoulder 440 Primary endpoint: change in degrees from ba

  14. Slide 14: Cellulite: Recently Initiated Phase 2b Study

    XIAFLEX® for Cellulite Recently Initiated Phase 2b Study Skin dimpling as a result of collagen fibrous septae, occurring mainly on the buttocks, lower limbs, and abdomen Affects 85-98% of women (est.) and rarely affects men Phase 2b Study Design Expected to enroll 350 women (18+ years) in U.S. 3 tre

  15. Slide 15: Cellulite: Positive Top-line Data from Phase 2a Study

    XIAFLEX® for Cellulite Positive Top-line Data from Phase 2a Study Top-line data from Phase 2a study: 150 women received up to three treatment sessions of drug or placebo according to randomization (5 high-dose (0.84mg): 5 mid (0.48mg): 5 low (0.06mg): 3 placebo) Mid and high level XIAFLEX® doses dem

  16. Slide 16: Human Lipomas

    XIAFLEX® for Human Lipomas Phase 2 Opt-In Study Managed by BioSpecifics Encapsulated deposits of benign fatty tumors; detected as bulges under the skin Potential to be Only Approved No FDA-approved pharmaceutical therapies available Nonsurgical Surgery not practical for patients with multiple lipoma

  17. Slide 17: Positive Phase Clinical Trial Results

    Positive Phase 2 Clinical Trial Results Open label, dose escalation Phase 2 trial Statistically significant (p<0.0001) reduction in primary endpoint of surface area of lipoma as measured by caliper, combining all patients Patients in highest dose group (75% of commercial dose) achieved best efficacy

  18. Slide 18: Lipomas in Canines

    XIAFLEX® for Lipomas in Canines Potential to be Only Approved Nonsurgical Therapy Key Complications Market Opportunity Chien-804 Trial Results Lipomas can seriously restrict motion in older dogs Surgery can be risky due to the use of general anesthesia - especially for older dogs 1.7M dogs affected

  19. Slide 19: Uterine Fibroids

    XIAFLEX® for Uterine Fibroids Clinical Trial to Begin in 2H16 Following Positive FDA Meeting in Late 2015 Definition & Key Complications U.S. Market Opportunity Encouraging Preclinical Data Sours of data: Cardozo ER, Clatk AD, Sanks NX, Hanne MB, Stegrann Bl. Segars JH. The estimates annual cost f u

  20. Slide 20: Lateral Hip Fat

    XIAFLEX® for Lateral Hip Fat Early Opt-In by Partner Endo Definition & Complications Fat accumulation is common among woman particularly as they age Often very difficult to improve its appearance through exercise and diet alone Patients frequently avoid exercise and are unable to restrict their calo

  21. Slide 21: Plantar Fibromatosis

    XIAFLEX® for Plantar Fibromatosis Early Opt-In by Partner Endo Definition & Complications Pain and disability caused by the thickening of the feet's deep connective tissue Formation of nodules or cords along tendons of the foot Patients often have Dupuytren’s disease, Peyronie’s disease and adhesive

  22. Slide 22: Endo Partnership for Development and Commercialization of XIAFLEX

    Endo Partnership for Development and Commercialization of XIAFLEX® $67.9M received in licensing, sublicensing, milestone, >$67.9M Received COGS, and royalty payments as of September 30, 2015 as of Sept. 30, 2015 Recently received $8.25M lump sum payment for ex-U.S. COGS by non-affiliates Low double

  23. Slide 23: Strong IP Portfolio

    Strong IP Portfolio Long-term patent protection for XIAFLEX® Dupuytren’s Contracture Drug product composition patent until 2028 Biologic Exclusivity until 2022 Peyronie’s Disease Orphan Drug protection in U.S. until 2020 Drug product composition patent until 2028 Patents and Patent Applications Owne

  24. Slide 24: Consistently Profitable Annually

    Consistently Profitable Annually Financial Highlights (unaudited) For the nine months ended 09/30/15 09/30/14 Cash and equivalents, and investments $32,824,471 $21,961,252 Income Statement Revenues $16,611,268 $9,396,976 Other income 65,056 53,189 Costs and expenses (6,062,469) (5,296,263) Provision

  25. Slide 25: Anticipated Upcoming Pipeline Milestones

    Anticipated Upcoming Pipeline Milestones O Phase 2 placebo-controlled opt-in trial top-line i * Bitar Lipolias results in 2Q16 1 Initiate clinical trial in 2H16 following FDA meeting in ane Fibroide* Uterine Fibroids late 2015 Adhesive Capsulitis OU Initiate Phase 2b trial following 1Q16 FDA discuss

  26. Slide 26: Innovators in the development & commercialization of injectable collagenase

    Innovators in the development & commercialization of INJECTABLE COLLAGENASE Pan d — er BioSpecifics February 2016

BioSpecifics Technologies — Investor Presentation (February 2016) on 6ix